Research Progress of Biomakers Proteomics-based in Lung Cancer

作者: Zhengang Chen , Hui Xie , Guangshun Wang

DOI: 10.3779/J.ISSN.1009-3419.2015.06.11

关键词: ProteomicsBiomarker (medicine)Protein expressionBiomarker discoveryPredictive biomarkerLung cancerProteomics methodsCancerBioinformaticsMedicine

摘要: Proteomic technologies can be applied to cancer research detect differential protein expression that could find biomakers. Lung biomarker discovery is significant due its anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of lung cancer. Therefore, there an indeed need identify new biomarkers for diagnosis serve open novel therapeutic means. This article briefly introduces the latest reports proteomic studies It contains diagnostic, prognostic, predictive biomarkers, a summary based on most recent literature our own work.

参考文章(49)
Bruno Schremmer, Yefim Manevich, Sheldon I. Feinstein, Aron B. Fisher, Peroxiredoxins in the lung with emphasis on peroxiredoxin VI. Sub-cellular biochemistry. ,vol. 44, pp. 317- 344 ,(2007) , 10.1007/978-1-4020-6051-9_15
Hee Seok Lee, Jun Won Park, Oleg Chertov, Simona Colantonio, John T. Simpson, Matthew J. Fivash, Chong Woo Yoo, Geon Kook Lee, Jae Ill Zo, Heung Tae Kim, Hark Kyun Kim, Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer. Pathology International. ,vol. 62, pp. 28- 35 ,(2012) , 10.1111/J.1440-1827.2011.02783.X
Gu-Qing Zeng, Hong Yi, Peng-Fei Zhang, Xin-Hui Li, Rong Hu, Mao-Yu Li, Cui Li, Jia-Quan Qu, Xingming Deng, Zhi-Qiang Xiao, The Function and Significance of SELENBP1 Downregulation in Human Bronchial Epithelial Carcinogenic Process PLoS ONE. ,vol. 8, pp. e71865- ,(2013) , 10.1371/JOURNAL.PONE.0071865
Lijian Zhang, Jinfeng Chen, Yang Ke, Robert Mansel, Wen Jiang, Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome International Journal of Molecular Medicine. ,vol. 17, pp. 937- 944 ,(2006) , 10.3892/IJMM.17.5.937
Sonia Molina-Pinelo, María D Pastor, Luis Paz-Ares, None, VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients? Expert Review of Respiratory Medicine. ,vol. 8, pp. 1- 4 ,(2014) , 10.1586/17476348.2014.861744
YUHSAKU KANOH, TADASHI ABE, NORIYUKI MASUDA, TOHRU AKAHOSHI, Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncology Reports. ,vol. 29, pp. 469- 473 ,(2013) , 10.3892/OR.2012.2123
Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, Solange Peters, Heinrich Roder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu-Fang Hsu Schmitz, Kyung-Jae Na, David Carbone, Rolf Stahel, Egbert Smit, VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer. ,vol. 79, pp. 59- 64 ,(2013) , 10.1016/J.LUNGCAN.2012.10.006
Zhao Chen, Christine M. Fillmore, Peter S. Hammerman, Carla F. Kim, Kwok-Kin Wong, Non-small-cell lung cancers: a heterogeneous set of diseases Nature Reviews Cancer. ,vol. 14, pp. 535- 546 ,(2014) , 10.1038/NRC3775
A.M. Rodríguez-Piñeiro, S. Blanco-Prieto, N. Sánchez-Otero, F.J. Rodríguez-Berrocal, M. Páez de la Cadena, On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. Journal of Proteomics. ,vol. 73, pp. 1511- 1522 ,(2010) , 10.1016/J.JPROT.2010.03.005
Gaoming Xiao, Qionghui Lu, Cui Li, Wenxiang Wang, Yuejun Chen, Zhiqiang Xiao, Comparative proteome analysis of human adenocarcinoma Medical Oncology. ,vol. 27, pp. 346- 356 ,(2010) , 10.1007/S12032-009-9216-X